May 19, 2009
Study results announced for Intuniv extended-release for ADHD
In January 2009, Shire filed a resubmission to the FDA of the New Drug Application to support the treatment of ADHD in children and adolescents. Intuniv is currently being studied as a once-daily, extended release formulation of guanfacine designed to provide steady delivery of drug throughout the day.
For more information call (800) 536-7878 or visit www.shire.com.